Humoral immunity in HIV-1 exposure: Cause or effect of HIV resistance?

被引:19
|
作者
Lopalco, L [1 ]
机构
[1] Ist Sci San Raffaele, Clin Infect Dis, I-20127 Milan, Italy
关键词
ESN; HIV resistance; humoral immunity; LTNP; mucosal immunity; neutralising antibodies;
D O I
10.2174/1570162043484951
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
More than two decades since its discovery, human immunodeficiency virus (HIV) epidemic is still a major burden for health, social and economical reasons on all over the world. Despite the huge effort in basic and applied research, aimed to control virus spread and to design effective therapeutic strategies, an HIV vaccine is not available yet and current therapeutics approaches cannot prevent the infection. To date, both host genetic repertoire, innate and acquired immune responses, viral mutation or attenuation have been invoked to explain the higher or lower individual Susceptibility to the infection. The existence of sonic people somewhat "immune" from infection, despite dealing with repeated HIV exposure, as well as the extremely slow disease progression in some HIV infected individuals, offers valuable cities to elucidate mechanisms underlying natural HIV resistance. Strikingly, both Such cohorts, the so-called Exposed Seronegative (ESN, EU, HEPS) and the Slow Progressor (SP, LTNP, LTS) individuals have common immune responses, e.g. the generation of neutralising antibodies directed against common targets, which call play a protective role in Virus entry and/or spread. This review focuses On naturally occurring humoral responses to HIV exposure/infection. Moreover, whether such antibodies are induced in response to a peculiar scenario of HIV infection or are generated in the context of all individual innate mode to clear Virus infection is a puzzling question, which will be addressed here. The comprehension of mechanisms of natural resistance to HIV infection may have implications for the identification of anti-viral novel strategies and in particular for the development of innovative diagnostics, therapeutics and vaccine design.
引用
收藏
页码:127 / 139
页数:13
相关论文
共 50 条
  • [41] HIV-1 Vif, APOBEC, and Intrinsic Immunity
    Ritu Goila-Gaur
    Klaus Strebel
    Retrovirology, 5
  • [42] Innate immunity in acute HIV-1 infection
    Borrow, Persephone
    CURRENT OPINION IN HIV AND AIDS, 2011, 6 (05) : 353 - 363
  • [43] Innate immunity against HIV-1 infection
    Altfeld, Marcus
    Gale, Michael, Jr.
    NATURE IMMUNOLOGY, 2015, 16 (06) : 554 - 562
  • [44] The evolutionary adaptation of HIV-1 to specific immunity
    da Silva, J
    CURRENT HIV RESEARCH, 2003, 1 (03) : 363 - 371
  • [45] HIV-1 drug resistance and resistance testing
    Clutter, Dana S.
    Jordan, Michael R.
    Bertagnolio, Silvia
    Shafer, Robert W.
    INFECTION GENETICS AND EVOLUTION, 2016, 46 : 292 - 307
  • [46] HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria
    Oluniyi, Paul E.
    Ajogbasile, Fehintola, V
    Zhou, Shuntai
    Fred-Akintunwa, Iyanuoluwa
    Polyak, Christina S.
    Ake, Julie A.
    Tovanabutra, Sodsai
    Iroezindu, Michael
    Rolland, Morgane
    Happi, Christian T.
    AIDS, 2022, 36 (01) : 137 - 146
  • [47] HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde
    Goncalves, Paloma
    Barreto, Jorge
    Santos, Menilita
    Leal, Silvania
    Marcelino, Jose
    Abecasis, Ana
    Palladino, Claudia
    Taveira, Nuno
    AIDS, 2024, 38 (08) : 1101 - 1110
  • [48] HIV-1 Entry, Inhibitors, and Resistance
    Lobritz, Michael A.
    Ratcliff, Annette N.
    Arts, Eric J.
    VIRUSES-BASEL, 2010, 2 (05): : 1069 - 1105
  • [49] Antiretroviral drug resistance in HIV-1
    George J. Hanna
    Richard T. D’Aquila
    Current Infectious Disease Reports, 1999, 1 (3) : 289 - 297
  • [50] Testing for HIV-1 drug resistance
    Hanna, GJ
    Caliendo, AM
    MOLECULAR DIAGNOSIS, 2001, 6 (04): : 253 - 263